Clinical Trial

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-24; most recent amendment 2026-06-02.
Trial Details
NCT Number NCT06853015
Lead Sponsor Shirley Ryan AbilityLab
Conditions SCI - Spinal Cord Injury
Enrollment 27 participants
Start Date 2025-02-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03